Xbrane Biopharma AB (STU:7XB) Long-Term Capital Lease Obligation : €3.48 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB Long-Term Capital Lease Obligation?

Xbrane Biopharma AB's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €3.48 Mil.

Xbrane Biopharma AB's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (€3.90 Mil) to Dec. 2023 (€3.82 Mil) and declined from Dec. 2023 (€3.82 Mil) to Mar. 2024 (€3.48 Mil).

Xbrane Biopharma AB's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€3.55 Mil) to Dec. 2022 (€2.64 Mil) but then increased from Dec. 2022 (€2.64 Mil) to Dec. 2023 (€3.82 Mil).

Xbrane Biopharma AB Long-Term Capital Lease Obligation Historical Data

The historical data trend for Xbrane Biopharma AB's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Long-Term Capital Lease Obligation Chart

Xbrane Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.60

0.39

3.55

2.64

3.82

Xbrane Biopharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															2.71	2.41	3.90	3.82	3.48

Xbrane Biopharma AB (STU:7XB) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Xbrane Biopharma AB Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Xbrane Biopharma AB (STU:7XB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

XBRANE:Sweden 7XB:Germany

Address

Retzius vag 8, Solna, SWE, 171 65

Website

https://www.xbrane.com

Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (STU:7XB) Headlines

No Headlines